Graves Ophthalmopathy Market Overview
The most common extrathyroidal symptom of Graves' illness is ophthalmopathy, sometimes called thyroid-associated ophthalmopathy and thyroid eye disease. This autoimmune condition causes the orbit to become inflamed as a result of the generation of autoantibodies. The thyroid and orbit both share a protein that the autoantibodies are thought to target.
&nbsp;
Graves Ophthalmopathy Epidemiology Segmentation in the 7MM from 2019 to 2032
<ul>
<li>Prevalent Cases</li>
<li>Diagnosed Prevalent Cases</li>
<li>Gender-specific Diagnosed Prevalent Cases</li>
<li>Diagnosed Prevalent Cases by Chronicity</li>
<li>Moderate-to-severe Drug-treated Cases of Acute Graves&rsquo; Ophthalmopathy</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/graves-ophthalmopathy-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Graves Ophthalmopathy Epidemiology</a> Insights (2022)
The Total Graves Ophthalmopathy prevalent cases in the 7MM were ~2.3 million cases in 2022
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/graves-ophthalmopathy-market" target="_blank" rel="noopener noreferrer">Graves Ophthalmopathy Market</a> Insight (2022)
The Graves Ophthalmopathy Market size in the 7MM was valued ~USD 2 billion in 2022
&nbsp;
Graves Ophthalmopathy Market Strengths
<ul>
<li>Recent FDA approval of Horizon&rsquo;s TEPEZZA</li>
<li>Efforts to increase patient and clinician awareness</li>
</ul>
&nbsp;
Graves Ophthalmopathy Market Opportunities
<ul>
<li>Lack of availability of disease-modifying treatment</li>
<li>Development of ocular drug discovery programs</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/graves-ophthalmopathy-pipeline-insight" target="_blank" rel="noopener noreferrer">Graves Ophthalmopathy Emerging Drugs</a> and key companies
<ul>
<li>Batoclimab (IMVT 1401): Immunovant Sciences</li>
<li>COSENTYX (secukinumab): Novartis</li>
<li>VRDN-001: Viridian Therapeutics</li>
<li>Linsitinib: Sling Therapeutics</li>
<li>Aflibercept: Regeneron Pharmaceuticals</li>
<li>VB421: ValenzaBio, and others</li>
</ul>

Graves Ophthalmopathy Market

Graves Ophthalmopathy Market Infographic

 Graves Ophthalmopathy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape